The effectiveness of botulinum toxin type A (BoNT-A) treatment in brazilian patients with chronic post-stroke spasticity: results from the observational, multicenter, prospective BCause study
| Autor: | Regina Helena Fornari Morganti Chueire, Lucia Helena Costa Mercuri, Pascal Maisonobe, Marcelo Riberto, João Amaury Frances, Alexandre Luiz Longo, Tae Mo Chung, Denise Rodrigues Xerez, Patricia Khan, Sergio Lianza, Viviane C Ruiz-Schutz, Ana Cristina Ferreira Garcia Amorim |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Health Toxicology and Mutagenesis medicine.medical_treatment lcsh:Medicine Toxicology Article Goal Attainment Scaling Young Adult 03 medical and health sciences 0302 clinical medicine ACIDENTE VASCULAR CEREBRAL Quality of life Internal medicine medicine Clinical endpoint Humans pain cardiovascular diseases 030212 general & internal medicine Spasticity Botulinum Toxins Type A Stroke Aged Rehabilitation business.industry lcsh:R spasticity Middle Aged medicine.disease stroke nervous system diseases Treatment Outcome medicine.anatomical_structure Neuromuscular Agents quality of life Muscle Spasticity Chronic Disease Upper limb Female Observational study medicine.symptom business Brazil 030217 neurology & neurosurgery |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP Toxins, Vol 12, Iss 770, p 770 (2020) Toxins Volume 12 Issue 12 |
| Popis: | Botulinum toxin type A (BoNT-A) is an effective treatment for post-stroke spasticity however, some patients cannot access treatment until &ge 1 year post-stroke. This Brazilian post-marketing study (NCT02390206) assessed the achievement of person-centered goals in patients with chronic post-stroke spasticity after a BoNT-A injection. Patients had a last documented stroke &ge 1 year before study entry and post-stroke upper limb (UL) spasticity, with or without lower limb (LL) spasticity. Patients received BoNT-A injections at baseline (visit 1) and visit 2 (3&ndash 6 months). Primary endpoint was responder rate (achievement of primary goal from Goal Attainment Scaling (GAS)) at visit 2. Overall, 204 patients underwent GAS evaluation at visit 2, mean (SD) age was 56.4 (13.2) years and 90.7% had LL spasticity. Median (range) time between first stroke and onset of spasticity was 3.6 (0&minus 349) months, onset of spasticity and first injection was 22.7 (0&minus 350) months and waiting time for a rehabilitation appointment was 9.0 (1&minus 96) months. At visit 2, 61.3% (95% CI: 54.4, 67.7) of patients were responders, which was similar for UL and LL primary goals (57.8% [95% CI: 49.9, 65.3] vs. 64.1% [95% CI: 48.4, 77.3]). This study provides evidence to support the effectiveness of BoNT-A treatment for chronic post-stroke spasticity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|